CLRB — Cellectar Biosciences, Inc.

Is CLRB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Cellectar Biosciences, Inc. (CLRB) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.01. The rating moved from Oversold to Strong Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Cellectar Biosciences is a clinical-stage, small-cap biotech with binary upside tied to trial readouts, partnering deals, or regulatory actions. The combination of limited liquidity, potential dilution risk, and a sector backdrop favoring large-cap pharma makes the near-term outlook uncertain; upside requires positive clinical or corporate developments while downside would likely follow negative data or financing needs.

Key factors

  • Clinical-stage biotech with binary, event-driven value tied to trial readouts or partnering/licensing outcomes
  • Very low current share price and likely low market capitalization, implying limited liquidity and high short-term volatility
  • Potential catalysts include clinical data, regulatory updates, or partnering deals that could materially re-rate the equity
  • Sector environment favoring large-cap pharma and defensives could limit investor interest in micro-/small-cap biotechs in the near term
  • Convertible-debt/dilution theme in the sector increases the probability of future equity raises or dilutive financings
  • No recent EDGAR filings or strong social sentiment data available to confirm positive momentum or institutional buying

Risks

  • Binary clinical or regulatory setbacks that could produce sharp negative price moves
  • Financing risk and dilution from equity raises, convertible notes, or other capital markets activity
  • Low liquidity and wide bid-ask spreads magnify downside on negative news and limit ability for investors to enter/exit positions
  • Competition in the therapeutic areas targeted and potential negative readthroughs from larger pharmaceutical players
  • Lack of transparent recent financial disclosures in the provided data creates uncertainty about cash runway and burn rate
  • Broader sector rotations away from small-cap biotechs could depress valuation absent clear, near-term catalysts

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CLRB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.